Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN

Chiou Feng Lin, Kung Chia Young, Chyi Huey Bai, Bu Chin Yu, Ching Ting Ma, Yu Chieh Chien, Chiu Ling Chiang, Chao Sheng Liao, Hsin Wen Lai, Chiung Wen Tsao

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR γ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPAR γ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. We found that lower doses (2) production (via cyclooxygenase-2, COX-2), and activation of Akt in RAW 264.7 murine macrophages. However, rosiglitazone did not inhibit the production of reactive oxygen species (ROS). In PTEN knockdown (shPTEN) cells exposed to LPS, rosiglitazone did not inhibit NO release, PGE2 production, and activation of Akt. These cells had elevated basal levels of iNOS, COX-2, and ROS. However, higher doses (25-100 M) of rosiglitazone, without LPS stimulation, did not block NO release and PGE2 productions, but they inhibited p38 MAPK phosphorylation and blocked ROS generation in shPTEN cells. In addition, rosiglitazone caused G1 arrest and reduced the number of cells in S + G2/M phase, leading to growth inhibition. These results indicate that the anti-inflammatory property of rosiglitazone is related to regulation of PTEN independent of inhibition on ROS production. However, rosiglitazone affected the dependence of PTEN-deficient cell growth on ROS.

Original languageEnglish
Article number787924
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

rosiglitazone
Inflammation
Reactive Oxygen Species
Growth
PPAR gamma
Cyclooxygenase 2
Dinoprostone
Anti-Inflammatory Agents
Chemical activation
Phosphorylation
Macrophages
G2 Phase
Cell growth
p38 Mitogen-Activated Protein Kinases
Phosphoric Monoester Hydrolases
Cell Division

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. / Lin, Chiou Feng; Young, Kung Chia; Bai, Chyi Huey; Yu, Bu Chin; Ma, Ching Ting; Chien, Yu Chieh; Chiang, Chiu Ling; Liao, Chao Sheng; Lai, Hsin Wen; Tsao, Chiung Wen.

In: BioMed Research International, Vol. 2014, 787924, 2014.

Research output: Contribution to journalArticle

Lin, CF, Young, KC, Bai, CH, Yu, BC, Ma, CT, Chien, YC, Chiang, CL, Liao, CS, Lai, HW & Tsao, CW 2014, 'Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN', BioMed Research International, vol. 2014, 787924. https://doi.org/10.1155/2014/787924
Lin, Chiou Feng ; Young, Kung Chia ; Bai, Chyi Huey ; Yu, Bu Chin ; Ma, Ching Ting ; Chien, Yu Chieh ; Chiang, Chiu Ling ; Liao, Chao Sheng ; Lai, Hsin Wen ; Tsao, Chiung Wen. / Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. In: BioMed Research International. 2014 ; Vol. 2014.
@article{2fd45ff86aab4220a2e084caa9f46b74,
title = "Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN",
abstract = "Peroxisome proliferator-activated receptor gamma (PPAR γ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPAR γ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. We found that lower doses (2) production (via cyclooxygenase-2, COX-2), and activation of Akt in RAW 264.7 murine macrophages. However, rosiglitazone did not inhibit the production of reactive oxygen species (ROS). In PTEN knockdown (shPTEN) cells exposed to LPS, rosiglitazone did not inhibit NO release, PGE2 production, and activation of Akt. These cells had elevated basal levels of iNOS, COX-2, and ROS. However, higher doses (25-100 M) of rosiglitazone, without LPS stimulation, did not block NO release and PGE2 productions, but they inhibited p38 MAPK phosphorylation and blocked ROS generation in shPTEN cells. In addition, rosiglitazone caused G1 arrest and reduced the number of cells in S + G2/M phase, leading to growth inhibition. These results indicate that the anti-inflammatory property of rosiglitazone is related to regulation of PTEN independent of inhibition on ROS production. However, rosiglitazone affected the dependence of PTEN-deficient cell growth on ROS.",
author = "Lin, {Chiou Feng} and Young, {Kung Chia} and Bai, {Chyi Huey} and Yu, {Bu Chin} and Ma, {Ching Ting} and Chien, {Yu Chieh} and Chiang, {Chiu Ling} and Liao, {Chao Sheng} and Lai, {Hsin Wen} and Tsao, {Chiung Wen}",
year = "2014",
doi = "10.1155/2014/787924",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN

AU - Lin, Chiou Feng

AU - Young, Kung Chia

AU - Bai, Chyi Huey

AU - Yu, Bu Chin

AU - Ma, Ching Ting

AU - Chien, Yu Chieh

AU - Chiang, Chiu Ling

AU - Liao, Chao Sheng

AU - Lai, Hsin Wen

AU - Tsao, Chiung Wen

PY - 2014

Y1 - 2014

N2 - Peroxisome proliferator-activated receptor gamma (PPAR γ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPAR γ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. We found that lower doses (2) production (via cyclooxygenase-2, COX-2), and activation of Akt in RAW 264.7 murine macrophages. However, rosiglitazone did not inhibit the production of reactive oxygen species (ROS). In PTEN knockdown (shPTEN) cells exposed to LPS, rosiglitazone did not inhibit NO release, PGE2 production, and activation of Akt. These cells had elevated basal levels of iNOS, COX-2, and ROS. However, higher doses (25-100 M) of rosiglitazone, without LPS stimulation, did not block NO release and PGE2 productions, but they inhibited p38 MAPK phosphorylation and blocked ROS generation in shPTEN cells. In addition, rosiglitazone caused G1 arrest and reduced the number of cells in S + G2/M phase, leading to growth inhibition. These results indicate that the anti-inflammatory property of rosiglitazone is related to regulation of PTEN independent of inhibition on ROS production. However, rosiglitazone affected the dependence of PTEN-deficient cell growth on ROS.

AB - Peroxisome proliferator-activated receptor gamma (PPAR γ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPAR γ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. We found that lower doses (2) production (via cyclooxygenase-2, COX-2), and activation of Akt in RAW 264.7 murine macrophages. However, rosiglitazone did not inhibit the production of reactive oxygen species (ROS). In PTEN knockdown (shPTEN) cells exposed to LPS, rosiglitazone did not inhibit NO release, PGE2 production, and activation of Akt. These cells had elevated basal levels of iNOS, COX-2, and ROS. However, higher doses (25-100 M) of rosiglitazone, without LPS stimulation, did not block NO release and PGE2 productions, but they inhibited p38 MAPK phosphorylation and blocked ROS generation in shPTEN cells. In addition, rosiglitazone caused G1 arrest and reduced the number of cells in S + G2/M phase, leading to growth inhibition. These results indicate that the anti-inflammatory property of rosiglitazone is related to regulation of PTEN independent of inhibition on ROS production. However, rosiglitazone affected the dependence of PTEN-deficient cell growth on ROS.

UR - http://www.scopus.com/inward/record.url?scp=84897516838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897516838&partnerID=8YFLogxK

U2 - 10.1155/2014/787924

DO - 10.1155/2014/787924

M3 - Article

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 787924

ER -